5.305

3.21% 0.165

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $5.305, with a volume of 4.11M. It is up +3.21% in the last 24 hours and up +30.02% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Previous Close:

$5.14

Open:

$5.14

24h Volume:

4.11M

Relative Volume:

0.77

Market Cap:

$1.62B

Revenue:

$75.13M

Net Income/Loss:

$-146.41M

P/E Ratio:

-10.82

EPS:

-0.4904

Net Cash Flow:

$-174.43M

1W Performance:

+29.71%

1M Performance:

+30.02%

6M Performance:

+51.14%

1Y Performance:

+165.25%

1-Day Range:

$5.04

$5.43

1-Week Range:

$3.94

$5.43

52-Week Range:

$1.94

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (619)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	5.305	1.57B	75.13M	-146.41M	-174.43M	-0.4904
VRTX Vertex Pharmaceuticals Inc	434.78	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.23	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	811.33	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.29	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	155.83	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

10:14 AM

Truist raises AbCellera stock price target on clinical data promise By Investing.com - Investing.com Canada

10:14 AM

09:55 AM

Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade - Yahoo Finance

09:55 AM

04:29 AM

ABCL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

04:29 AM

May 21, 2026

ABCL Stock Climbs As Earnings Beat, Drug Data Fuel Bullish Outlook - StocksToTrade

May 21, 2026

May 20, 2026

10 Best Penny Stocks to Buy for Long Term - Insider Monkey

May 20, 2026

Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

May 20, 2026

Abcellera Biologics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 20, 2026

May 19, 2026

AbCellera Biologics : Corporate Overview - marketscreener.com

May 19, 2026

ABCL stock clocks best week since February on clinical data anticipation, Baker Bros stake boost - MSN

May 19, 2026

May 18, 2026

AbCellera Biologics Inc.Common Shares (NQ: ABCL - FinancialContent

May 18, 2026

Director John Montalbano adds 20,000 AbCellera (ABCL) shares in open trade - Stock Titan

May 18, 2026

May 17, 2026

AbCellera Biologics Q1 earnings call highlights - MSN

May 17, 2026

May 15, 2026

Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14 - Sahm

May 15, 2026

May 14, 2026

Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN

May 14, 2026

AbCellera Biologics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-05-14 - Seeking Alpha

May 14, 2026

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Yahoo Finance

May 14, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2026 Earnings Call Transcript - Insider Monkey

May 14, 2026

May 13, 2026